43 a Determined by HPLC using the same conditions as those for compound purity analyses (see below). After 46 h, the reactions were worked up, and DIM-Ph-4-X + OMs -s were isolated in 36% and 32% yields, respectively. 
Supplementary

OMs
-s (oxidized compounds). Individual compounds are designated by their X substituent at the phenyl ring 4-position (X = CF 3 , CO 2 Me, Cl, OMe and CO 2 Tables 1 and 2 were determined from these concentration-viability response curves. -. MOLM-13 and OCI-AML-2 AML cells were grown in RPMI 1640 medium with and without 10% fetal bovine serum (FBS) and then treated for 24 h with 0.01, 0.1, 1.0 and 10.0 μM in DMSO (0.125% final concentration) or DMSO alone. Inhibition of cell viability was determined by measuring the decline in ATP levels as described in the Methods. Viabilities of treated cells relative to those of the vehicle-treated control cells were expressed as the ratios of means of triplicates ± SD × 100. Solid lines represent OCI-AML-2 (AML-2) (▲) and MOLM-13 (◆) cells grown in the presence of FBS and dashed lines those grown in its absence. IC 50 values were determined from interpolation of the concentration-viability curves and are listed in Table 4 . Table 1 were determined by interpolation of these curves. 
H). IC 50 values listed in
Supplementary
Compound purity analyses
Reversed-phase HPLC analysis of target compounds in Supplementary Table 2 was performed on a Shimadzu 20A HPLC system using elution from a 4.6-mm × 150-mm TITAN C 18 column (5-μm particle size), with the UV absorbance detection at 254 nm, and the mixed A/B solvent system described below at a flow rate of 1.0 mL/min: Solvent A: 0.2% H 3 PO 4 in H 2 O Solvent B: 0.2% H 3 PO 4 in MeOH Using the solvent gradient 35 min 70% A/30% B to 5% A/95% B (0-20 min) followed by 95% B (20-33 min) and then 5% A/95% B to 70% A/30% B (2-min recycle).
Reported leukemia cell mutations, gene transpositions and over or under-expressed proteins
DIM-Ph-4-CF 3 + docks to NR4A1 LBD structure 3V3Q
Although the pose in Figure S6A shows that the 4-CF 3 -Ph group and benzo portions of the indole rings of the cation are more exposed on the LBD surface, a partial π-π stacking between its phenyl ring and that of the H5 Tyr122 and two F···HO interactions between its Fs and the Tyr122 OH are observed. One indole NH could H-bond with the H5 Arg119 C = O and the other indole NH could H-bond with the H1 Pro46 C = O. The pose in Figure  S6B suggests a H-bond between one F of the cation and the helix H12 Phe261 NH and hydrophobic interactions between its phenyl ring and H4 Phe112 and Leu113, H11 Leu239 and H12 Ile260 side-chains. One indole NH of the cation could H-bond with the H5 Glu114 CO 2 H or the H4 Ser110 OH.
Docking of Csn-B to the apo-NR4A1 LBD (PDB 2QW4)
Our docked pose for Csn-B showed that its 2-octanoyl side chain could extend into the interior of the allosteric pocket to form van der Waals contacts with several pocket residues ( Figure 3E ). Its 3-OH and 5-OH groups could form H-bonds with the loop L7-8 Val167 backbone C = O and the helix H7 His163 backbone C = O and N, respectively. A partial π-π stacking interaction could occur between the phenyl rings of Csn-B and the H5 Tyr122.
Supplemental synthetic methods and target compound characterizations General methods
Chemicals and solvents were obtained from commercial sources and used without purification. Unless mentioned, anhydrous and/or oxygen-sensitive reactions were carried out under argon gas. Reactions were monitored by thin-layer chromatography on silica gel (mesh size 60, F 254 ) with visualization under UV light. Unless otherwise specified, the standard workup involved washing the organic extract with water and brine and then drying it over anhydrous sodium sulfate followed by filtration and concentration under reduced pressure. Chromatography refers to flash column chromatography on silica gel (Merck 60, 230-400 mesh). Most experimental procedures were not optimized. Melting points of compounds were determined in capillary tubes using a Mel-Temp II apparatus and were not corrected. Infrared spectra of powdered or liquid samples were obtained using an FT-IR Mason satellite spectrophotometer. Unless mentioned, 1 H and 13 C NMR spectra were obtained on compounds dissolved in CDCl 3 or the specified solvent using a 300-MHz Varian Unity Inova or a 400-MHz ECS Jeol spectrometer. Proton chemical shifts are expressed in ppm (δ) relative to CHCl 3 as the internal standard. High-resolution mass spectra were determined using an AgilentTechnologies 6224A accurate mass TOF LC/MS system at Sanford-Burnham Medical Research Institute (Lake Nona, FL). A Shimadzu HPLC system was used to analyze the oxidation rate of DIM-Ph-4-CF 3 to DIM-Ph-4-CF 3 + OMs - (Supplementary Table 1 ) and the purity of target molecules (Supplementary Table  2 ). The purity of compounds used in biological assays was ≥ 95% as determined by HPLC. Compound nomenclature used in these Methods follows that currently employed by Chemical Abstracts.
Condensation of indole with 4-substituted benzaldehydes produces the corresponding 4-substituted di(1H-indol-3-yl)methylbenzenes (DIM-Ph-4-Xs)
A reported procedure was used to generate the CeCl 3 •7 H 2 O-NaI-SiO 2 catalyst [9] . Briefly, to a solution of CeCl 3 •7 H 2 O (0.9 mmol) and NaI (0.9 mmol) in CH 3 CN (21 mL) was added silica gel (13.9 mmol). This mixture was stirred for approximately 21 h before the solvent was removed at reduced pressure to yield a yellow solid. To this solid was added CH 3 CN (7.5 mL), indole (6.0 mmol) and the 4-substituted benzaldehyde (3.0 mmol).
The mixture was stirred for 22- 
O rinse). The filtrate was concentrated at reduced pressure, and the residue was purified by chromatography to give the 4-substituted di(1H-indol-3-yl)methylbenzene (DIMPh-4-X). 
3,3ʹʹ-[(4-(
7-IndoleH), 7.45 (d, J = 8.3 Hz, 2H, 2,6-ArH), 7.83 (d, J = 8.3 Hz, 2H, 3,5-ArH), 10.83 ppm (s, 2H, NH).
4-[Di(1H-indol-3-yl)methyl]benzoic acid (DIM-
Ph-4-CO 2 H) [42]
To a stirred solution of DIM-Ph-4-CO 2 Me (700 mg, 1.84 mmol) in MeOH (20 mL) was added 5 M aq NaOH (1.84 mL, 9.20 mmol). This mixture was heated at reflux under argon for 50 min, cooled to room temperature and acidified (1 N HCl, 40 mL) and extracted (EtOAc, 130 mL). The organic extract was washed (brine) and 
Oxidation of di(1H-indol-3-yl)methyl(4-Xbenzene)s to their di(1H-indol-3-yl)(4-X-phenyl) methylium mesylates
A reported procedure for the synthesis of tris(1-alkylindol-3-yl)methylium salts [4] was adapted. To a solution of the di(1H-indol-3-yl)(4-X-phenyl)methane (0.5 mmol) in 1-butanol (5 mL) was added activated carbon powder (Norit ® , 10-25 mg) and MsOH (1.5 mmol). This mixture was stirred for more than 20 h under air and then filtered through a short pad of Celite ® . The filtrate was washed (water) and concentrated under reduced pressure. The brown residue was triturated (Et 2 O), collected by filtration using a sintered glass filter (Et 2 O wash) and dried at reduced pressure. The resultant solid was washed (Et 2 O, 4Í) and dried to give the product as a reddish-brown powder. Replacing 1-butanol by 2-butanol gave a similar yield. 1H-indol-3-yl)(4-trifluoromethylphenyl) Di (1H-indol-3-yl)(4-chlorophenyl) 
Di(
Oxidation of 4-Substituted Di(1H-indol-3-yl) methylbenzenes to (E)-3-[(1H-indol-3-yl)(4-X-phenyl)methylene]-3H-indoles (X = CF 3 and CO 2 Me)
A reported method [6] was used. To a stirred solution of the DIM-Ph-4-X in MeCN was added 2,3-dichloro-5,6-dicyano-p-benzoquinone (DDQ) and stirring was continued at room temperature for 2-3 h. Chromatography produced a dark-red solid, which was washed with EtOAc (X = CF 3 ) or MeCN (X = CO 2 Me) and then with ether. The crude product was purified by chromatography to give the I(Ph-4-X)MI. 3-((1H-indol-3-yl)(4-trifluoromethylphenyl)  methylene)-3H-indole (I(Ph-4-CF 3 )MI) DIM-Ph-4-CF 3 (195 mg, 0.5 mmol) and DDQ (136 mg, 0.6 mmol) after reaction for 2 h 10 min, work-up and chromatography (5-10% MeOH/CH 2 Cl) produced 147 mg (76%) of I(Ph-4-CF 3 )MI as an orange powder, mp 241−244° C (dec 
(E)-
(E)-3-((1H-indol-3-yl)(4-methoxycarbonylphenyl) methylene)-3H-indole (I(Ph-4-CO 2 Me)MI)
DIM-Ph-4-CO 2 Me (230 mg, 0.60 mmol) and DDQ (165 mg, 0.73 mmol) after reaction for 3 h, work-up and chromatography (7- 
Conversion of (E)-3-((1H
-
Differential scanning calorimetry
Experiments were performed at a scanning rate of 1 K/min under 3.0 atm of pressure using an N-DSC II differential scanning calorimeter (Calorimetry Sciences Corp.). Samples contained NR4A1 LBD (20 µM, 0.51 mg/ml) alone or with compound (30 or 60 µM), and 5% DMSO in PBS, pH 7.4. The reference contained 5% DMSO in PBS. Data were analyzed using the NanoAnalyse software package (TA Instruments). Melting temperature (T m ) corresponds to the maximum thermal transition temperature. Calorimetric enthalpy (ΔH) was calculated as the area under the excess heat capacity function (C p ). ; and Cl, 22.6 Å 3 ) were calculated using the free online service for calculating molecular properties provided by Molinspiration Cheminformatics (Nova ulica, Slovensky Grob, Slovak Republic) [7] .
Computational methods
Volume calculation
Molecular modeling
Docking of the cation (DIM-Ph-4-CF 3 + ) of DIM-Ph-4-CF 3 + OMs -into the pocket corresponding to allosteric site 1 in the crystal structure of the human NR4A1 (TR3) LBD protein (PDB 2QW4) [43] employed BioMed Cache vs. 6.2 software, which is no longer supported by Fujitsu Limited, and our previously described methods [44] . Briefly, the LBP was derived by selecting all neighboring residues within a 10-Å radius to ensure that all residues were encompassed. In the docking process, the energyminimized pose of Csn-B was kept rigid to maintain the geometry used for docking by Wu and colleagues [45] , whereas the carbocation was allowed to be flexible. In both cases, the side chains of pocket residues were allowed to be flexible. The docked poses for Csn-B and DIM-Ph-4-CF 3 + ( Figure 3E ) were analyzed by measuring inter-atom distances after superposing the helical backbones of the docked NR4A1 LBD poses.
Docking of DIM-Ph-4-CF 3 + into allosteric sites 1 and 2 on the structure (PDB 3V3Q) [11] of the complex of the NR4A1 LBD with two molecules of the Csn-B analogue (structure in Figure S1 ) used the GOLD docking engine in the Discovery Studio 3.5 package (Accelrys Inc.). The LBP for each site was derived by selecting all neighboring residues within an 8-Å radius of the analogue [11] . The geometry of DIM-Ph-4-CF 3 + was optimized before docking and during docking was allowed to be flexible, whereas the side chains of pocket residues were kept rigid. Possible interactions between DIM-Ph-4-CF 3 + and the residues lining both sites were analyzed and are shown in Figure S6 .
Cancer cell line characteristics
HCT-116 colorectal carcinoma cells are poorly differentiated, express a constitutively active mutant p21ras (Ki-ras) proto-oncogene [13] and a mutant β-catenin, which is not inhibited by wild-type APC [14] , and over-express c-myc [13] . This cell line also expresses wild-type p53, PPARγ and NR4A1 [12] . Of the breast cancer lines, MCF-7 expresses estrogen receptors and its growth is estrogen-dependent [15, 18] , whereas MDA-MB-231 does not express estrogen receptors and its growth is estrogen-independent [18] . Wild-type tumor suppressor p53 and mutant nonfunctional p53 are expressed in MCF-7 and MDA-MB-231 cells, respectively [26] . NR4A1 is expressed in MCF-7 cells [1] , but not in MDA-MB-231 cells [1] , and PPARγ is expressed in both lines [17, 18] . Of the prostate cancer cell lines, LNCaP cells are androgen-dependent and express the mutant androgen receptor (AR) (Thr877Ala), which is activated by both the androgen dihydrotestosterone (DHT) and the anti-androgen hydroxyflutamide [25] . They also express low levels of PPARγ1 [24] and after treatment with the PPARγ ligand 15d-Pg J 2 express modest levels of PPARγ2 [24] . The calcium ionophore A23187, anti-cancer drug etoposide and androgen induce the expression of NR4A1 [27] . LAPC-4 cells are androgen-dependent and express wild-type AR [23, 28] . 22Rv1 cells are reported to grow independently of androgen in vivo and to express both a DHT and hydroxyflutamide-activated full-length AR(His874Tyr) mutant [25] and a truncated 80-KDa AR mutant [29] . They also express NR4A1 [24] , but not PPARγ [24] . The expression of NR4A1 and PPARγ in LAPC-4 cells [23] has not been reported. The growth of PC-3 cells, which are AR null, is androgen independent [25] . They weakly express PPARγ1 [25] and after treatment with 15d-Pg J 2 robustly express PPARγ2 [25] , A23187 or etoposide treatment induces their expression of NR4A1 [27] . PC-3 cells do not express p53 [26] , whereas the other three lines do [26] . The phosphatase and tensin homologue deleted on chromosome 10 (PTEN) enzyme is reported to antagonize AR transactivation and Akt-PI3K signaling, and its loss is associated with advanced prostate cancer [28] . PTEN is expressed and functional in LACP-4 [28] and 22Rv1 [28, 29] cells, although in the former its expression is reported to be low [29] , PTEN is absent in LNCaP and PC-3 cells [28] .
